{"commentary":{"count":33,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":23,"youtube":9,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04430192\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"LuTectomy","nct_id":"NCT04430192","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lutectomy-nct04430192. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"LuTectomy","arms":[{"description":"177Lu-PSMA-617 followed by prostatectomy","label":"177Lu-PSMA-617 followed by prostatectomy","type":"EXPERIMENTAL"}],"collaborators":["Movember Foundation","Medical Research Future Fund","Endocyte","E.J. Whitten Foundation Prostate Cancer Research Centre"],"completion_date":{"date":"2025-08-30","type":"ESTIMATED"},"conditions":["Prostatic Neoplasms"],"enrollment":{"count":20,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"177Lu-PSMA-617","type":"DRUG"}],"last_update":"2024-11-08","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","official_title":"Study of the Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Radionuclide Therapy Prior to Radical Prostatectomy in Men With High-risk Localised Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2022-12-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"To determine the radiation absorbed dose in the prostate and involved lymph nodes following one or two administrations of Lu-PSMA in men with HRCaP prior to radical prostatectomy","timeFrame":"Determined using imaging at 4, 24 and 96 hrs after administration of Lu-PSMA"}],"references":[{"citation":"Eapen RS, Buteau JP, Jackson P, Mitchell C, Oon SF, Alghazo O, McIntosh L, Dhiantravan N, Scalzo MJ, O'Brien J, Sandhu S, Azad AA, Williams SG, Sharma G, Haskali MB, Bressel M, Chen K, Jenjitranant P, McVey A, Moon D, Lawrentschuk N, Neeson PJ, Murphy DG, Hofman MS. Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. 2024 Mar;85(3):217-226. doi: 10.1016/j.eururo.2023.08.026. Epub 2023 Oct 26.","pmid":"37891072","type":"DERIVED"}],"start_date":{"date":"2020-08-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy","url":"https://clinicaltrials.gov/study/NCT04430192"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lutectomy-nct04430192"}